Technical Analysis for ATNF - 180 Life Sciences Corp.

Grade Last Price % Change Price Change
B 11.98 23.00% 2.24
ATNF closed up 23.0 percent on Monday, April 12, 2021, on 12.98 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical ATNF trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Expansion Breakout Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Wide Range Bar Range Expansion 0.00%
New 52 Week High Strength 0.00%
Parabolic Rise Strength 0.00%
Stochastic Reached Overbought Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Older End-of-Day Signals for ATNF ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Trending on StockTwits 15 minutes ago
60 Minute Opening Range Breakout about 7 hours ago
Rose Above Previous Day's High about 10 hours ago
New 52 Week High about 10 hours ago
3x Volume Pace about 10 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The Company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The Company’s primary platform is a novel program to treat fibrosis using anti-TNF, with its lead program in phase 2b/3 clinical trials.
Classification

Sector: Industrials
Industry: Conglomerates
Keywords: Biotechnology Clinical Medicine Immunology Pain Disease Inflammation Inflammatory Disease Inflammatory Diseases Fibrosis Cytokines Tumor Necrosis Factor Animal Physiology Stanford University Human Physiology

Is ATNF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 13.05
52 Week Low 1.9
Average Volume 3,355,522
200-Day Moving Average 7.34
50-Day Moving Average 5.81
20-Day Moving Average 6.98
10-Day Moving Average 7.86
Average True Range 1.25
ADX 39.57
+DI 54.91
-DI 8.46
Chandelier Exit (Long, 3 ATRs ) 9.29
Chandelier Exit (Short, 3 ATRs ) 8.72
Upper Bollinger Band 10.12
Lower Bollinger Band 3.85
Percent B (%b) 1.3
BandWidth 89.85
MACD Line 1.16
MACD Signal Line 0.69
MACD Histogram 0.4768
Fundamentals Value
Market Cap 216.02 Million
Num Shares 18 Million
EPS
Price-to-Sales 0.00
Price-to-Book 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.53
Resistance 3 (R3) 16.38 14.71 15.77
Resistance 2 (R2) 14.71 13.56 14.79 15.51
Resistance 1 (R1) 13.35 12.84 14.03 13.50 15.26
Pivot Point 11.68 11.68 12.03 11.76 11.68
Support 1 (S1) 10.32 10.53 11.00 10.47 8.70
Support 2 (S2) 8.65 9.81 8.73 8.45
Support 3 (S3) 7.29 8.65 8.19
Support 4 (S4) 7.44